FYB Stock Overview A biotechnology company, develops biosimilar drugs in Germany and Switzerland. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Formycon Historical stock prices Current Share Price €52.00 52 Week High €56.70 52 Week Low €37.75 Beta 0.83 1 Month Change 11.95% 3 Month Change 6.23% 1 Year Change -2.44% 3 Year Change -8.13% 5 Year Change 67.74% Change since IPO 471.43%
Recent News & Updates
Formycon AG Appoints Colin Bond as Director Nov 15
Fresenius Kabi and Formycon Receives U.S. FDA Approval for Biosimilar Otulfi (ustekinumab-aauz) Oct 01
Investor sentiment improves as stock rises 17% Sep 30
First half 2024 earnings released: €0.58 loss per share (vs €0.11 profit in 1H 2023) Aug 18
Formycon AG to Report First Half, 2024 Results on Aug 13, 2024 Aug 06
Investor sentiment improves as stock rises 15% Jun 06 See more updates
Formycon AG Appoints Colin Bond as Director Nov 15
Fresenius Kabi and Formycon Receives U.S. FDA Approval for Biosimilar Otulfi (ustekinumab-aauz) Oct 01
Investor sentiment improves as stock rises 17% Sep 30
First half 2024 earnings released: €0.58 loss per share (vs €0.11 profit in 1H 2023) Aug 18
Formycon AG to Report First Half, 2024 Results on Aug 13, 2024 Aug 06
Investor sentiment improves as stock rises 15% Jun 06
Price target decreased by 8.7% to €87.00 May 12
Formycon AG to Report Q1, 2024 Results on May 08, 2024 May 03
Full year 2023 earnings released: EPS: €4.76 (vs €2.62 in FY 2022) Apr 25
Formycon AG to Report Fiscal Year 2023 Final Results on Apr 25, 2024 Apr 13
Price target decreased by 12% to €96.25 Apr 11
New minor risk - Shareholder dilution Apr 01
Price target decreased by 8.9% to €105 Jan 30 Formycon AG has completed a Follow-on Equity Offering in the amount of €82.840247 million. Jan 30
New minor risk - Share price stability Oct 14
Price target decreased by 7.5% to €107 Sep 20
First half 2023 earnings released: EPS: €0.11 (vs €6.51 in 1H 2022) Sep 08
Formycon AG to Report First Half, 2023 Results on Aug 30, 2023 Aug 24
Price target decreased by 8.8% to €115 Aug 22
New minor risk - Share price stability Jul 07
Formycon Announces Submission of the Biologics License Application (Bla) for Fyb203, an Aflibercept Biosimilar Candidate to the U.S. Food and Drug Administration (Fda) Jun 29
Investor sentiment improves as stock rises 16% May 18
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Apr 29 Formycon AG has completed a Follow-on Equity Offering in the amount of €70.07 million. Feb 03
Price target increased to €126 Nov 16
First half 2022 earnings released: EPS: €6.51 (vs €0.92 loss in 1H 2021) Nov 01
Formycon AG Publishes Details of A Previously Undisclosed Pipeline Project – Fyb206 Is A Biosimilar Candidate for Keytruda (Pembrolizumab) Sep 20
Price target increased to €107 Sep 19
Formycon AG, Polpharma Biologics Group BV and Bioeq AG Announce European Commission Approval for FYB201/Ranivisio1 (Ranivisio - Ranibizumab), a Biosimilar to Lucentis2 (News with Additional Features) Aug 29
Formycon Ag Announces EU-Approval of FYB201/Ranivisio A Biosimilar to Lucentis Aug 27
Formycon's Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara in Phase III Study Aug 16
Formycon Announces FDA Approval of Fyb201/Cimerlitm1 (Ranibizumab-EQRN) as A Biosimilar Interchangeable with Lucentis®2 Aug 04
Formycon AG Announces Supervisory Board and Executive Changes Jul 02
Formycon's Biosimilar for Lucentis (Ranibizumab), Receives CHMP Recommendation from EMA Jun 25
Full year 2021 earnings: EPS and revenues miss analyst expectations May 22 Formycon AG Announces Changes to Its Executive Board
Formycon AG Announces Receipt of Market Authorization of from Medicines and Healthcare Products Regulatory Agency May 19
Price target increased to €87.00 Apr 28
Price target increased to €75.00 Apr 14
Price target decreased to €70.00 Sep 29
First half 2021 earnings released: €0.92 loss per share (vs €0.14 loss in 1H 2020) Sep 24
Formycon AG Provides Revenue Guidance for the Year 2021 Sep 21
Formycon AG and Bioeq AG Announce Submits Biologics License Application for FYB201 to U.S. Food and Drug Administration Aug 08
Formycon AG Provides Sales Guidance for the Fiscal Year 2021 Jun 30
Full year 2020 earnings released May 19
Formycon Receives Approval for Early Action for COVID-19 Drug FYB207 as Part of a Grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy Apr 27
Formycon Receives Positive Scientific Advice from Paul-Ehrlich-Institute for the COVID-19 Drug FYB207 and Assures GMP Manufacturing Capacities Feb 24
Formycon AG, Annual General Meeting, Sep 27, 2021 Feb 18
New 90-day high: €75.40 Feb 12
Formycon's Scientific Collaboration Partners Present FYB207 Results At International Keystone Symposium Jan 13
Price target raised to €46.45 Dec 11
New 90-day high: €51.00 Dec 10
Formycon AG and Bioeq GmbH Announce Launch of Phase III Study of FYB202, a Biosimilar Candidate for Stelara(R) (Ustekinumab) Nov 09
Formycon AG and Bioeq AG Announce Biologics License Application Resubmission Strategy for Fyb201 Has Been Adjusted Nov 08
New 90-day high: €37.50 Oct 24
New 90-day high: €30.70 Oct 05
First half earnings released Sep 25
Price target raised to €36.28 Sep 23
New 90-day high - €27.20 Sep 10
Formycon AG to Report Q1, 2020 Results on Jun 22, 2020 Jul 17 Shareholder Returns FYB DE Biotechs DE Market 7D -0.2% -0.8% -1.6% 1Y -2.4% -13.0% 6.8%
See full shareholder returns
Return vs Market: FYB underperformed the German Market which returned 6.8% over the past year.
Price Volatility Is FYB's price volatile compared to industry and market? FYB volatility FYB Average Weekly Movement 5.5% Biotechs Industry Average Movement 6.9% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: FYB has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: FYB's weekly volatility (5%) has been stable over the past year.
About the Company Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious retinal diseases, including diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranpoto, Uptera, and Ravegza names. The company’s pipeline includes FYB202, a biosimilar candidate for Stelara used in the treatment of Psoriasis, Crohn’s disease, and ulcerative colitis which has completed the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea that treats ophthalmology related diseases, including neovascular age-related macular degeneration that has completed Phase III clinical trials.
Show more Formycon AG Fundamentals Summary How do Formycon's earnings and revenue compare to its market cap? FYB fundamental statistics Market cap €926.99m Earnings (TTM ) €63.90m Revenue (TTM ) €60.80m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) FYB income statement (TTM ) Revenue €60.80m Cost of Revenue €53.22m Gross Profit €7.58m Other Expenses -€56.32m Earnings €63.90m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/24 07:12 End of Day Share Price 2024/12/23 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Formycon AG is covered by 15 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Gerhard Orgonas Berenberg Benjamin Thielmann Berenberg Simon Scholes First Berlin Equity Research GmbH
Show 12 more analysts 
